title: [Place of bisphosphonates in the primary andsecondary prophylaxis of osteoporotic fractures: the role of parenteral therapy--proposal to modify the standards of treatment].
abstract: Oral bisphosphonates are currently known as medicines of a first choice in the treatment of osteoporosis and in preventing age-related fractures. However, despite their advantages, these medicines are not free of limitations. The most significant one is a complicated way of tablet administration, requiring from patients to remain upright position and to take a tablet before a meal. This may make the administration of other, chronic medicines, such as thyroid hormones, more difficult. Complications of the therapy include dyspepsia and gastrointestinal disorders. Approximately 48% of individuals taking bisphosphonates once a week resign from therapy within one year from the beginning of the treatment. There is a group of individuals who cannot take bisphosphonates orally at all. The alternative here is an intravenous injection. Therefore, there is a need for modifications of the existing therapeutic standards for osteoporosis. It is also necessary to emphasise the significance of intravenous medicines in the treatment of this disease.
authors.affiliation: Klinika Ortopedii i Rehabilitacji, II Wydział Lekarski, Warszawski Uniwersytet Medyczny. jdeszcz@o2.pl
authors.forename: Jarosław
authors.initials: J
authors.lastname: Deszczyński
authors.forename: Tomasz
authors.initials: T
authors.lastname: Rawo
authors.forename: Tomasz
authors.initials: T
authors.lastname: Petelewicz
mesh_terms: D000284:Administration, Oral; D035843:Biomedical Research; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D007275:Injections, Intravenous; D058866:Osteoporotic Fractures / Q000517:prevention & control*; D010349:Patient Compliance
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates